JPH06343422A - Oligopeptide mixture and its production - Google Patents
Oligopeptide mixture and its productionInfo
- Publication number
- JPH06343422A JPH06343422A JP5165014A JP16501493A JPH06343422A JP H06343422 A JPH06343422 A JP H06343422A JP 5165014 A JP5165014 A JP 5165014A JP 16501493 A JP16501493 A JP 16501493A JP H06343422 A JPH06343422 A JP H06343422A
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- protein
- oligopeptide mixture
- molecular weight
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 32
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 28
- 108090000790 Enzymes Proteins 0.000 claims abstract description 28
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 24
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 22
- 235000021119 whey protein Nutrition 0.000 claims abstract description 20
- 108091005804 Peptidases Proteins 0.000 claims abstract description 15
- 239000004365 Protease Substances 0.000 claims abstract description 15
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 8
- 229940088598 enzyme Drugs 0.000 claims description 27
- 235000019658 bitter taste Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 235000019583 umami taste Nutrition 0.000 claims description 12
- 102000008192 Lactoglobulins Human genes 0.000 claims description 11
- 108010060630 Lactoglobulins Proteins 0.000 claims description 11
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 108090000317 Chymotrypsin Proteins 0.000 claims description 6
- 229960002376 chymotrypsin Drugs 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 241001446247 uncultured actinomycete Species 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 235000019607 umami taste sensations Nutrition 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000000172 allergic effect Effects 0.000 abstract description 3
- 208000010668 atopic eczema Diseases 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 241000186046 Actinomyces Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 239000000413 hydrolysate Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000005862 Whey Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- -1 aromatic amino acids Chemical class 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 235000021241 α-lactalbumin Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010043393 protease N Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54244—Beta lactoglobulin
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、低アレルギー性の食品
および経腸栄養剤に利用可能な、腸管吸収性に優れ、ア
ミノ酸バランスが良く、風味の良好な新規オリゴペプチ
ド混合物及びその製造法に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel oligopeptide mixture having excellent intestinal absorbability, good amino acid balance, and good taste, which can be used for foods with low allergenicity and enteral nutrition, and a method for producing the same. It is a thing.
【0002】[0002]
【従来の技術】乳幼児から小児に多いアトピー性体質者
は、その素因をたどれば、妊婦の妊娠期間中、特に妊娠
後期の抗原性の強い卵、牛乳、大豆製品、魚などの摂取
に起因するといわれている。したがって、妊娠中にはこ
れら抗原性の強い異種タンパク質の摂取を控えたほうが
望ましいが、逆にこれらは代表的なタンパク質源でもあ
るので、栄養摂取上困難な問題である。2. Description of the Related Art Atopic dispositions, which are often found in infants and children, can be traced to their predisposition due to ingestion of highly antigenic eggs, milk, soybean products, fish, etc. during pregnancy, especially during the pregnancy. It is said that. Therefore, it is desirable to refrain from ingesting these heterologous proteins having strong antigenicity during pregnancy, but on the contrary, since these are also typical protein sources, it is a problem in nutrition intake.
【0003】また、既にアレルギー体質になってしまっ
ている人にとっても同様にタンパク質源となる食品の摂
取制限は、食品の選択上大きな問題である。Also, for those who have already become allergic, limiting the intake of foods that are protein sources is a big problem in selecting foods.
【0004】一方、手術前および手術後の栄養補給のた
めに用いられている経腸栄養剤については、未分解のタ
ンパク質を用いたものは消化不良が、アミノ酸混合物を
用いたものは下痢や腹部膨満症状の発生が問題となるこ
とが多い。また、腸管からの吸収速度については、アミ
ノ酸混合物よりもオリゴペプチドの方が優れていること
が明らかになっている。On the other hand, with respect to enteral nutritional agents used for nutritional supplementation before and after surgery, those using undegraded protein are indigestible, and those using an amino acid mixture are diarrhea and abdomen. The occurrence of bloating symptoms is often a problem. Further, it has been revealed that the oligopeptide is superior to the amino acid mixture in terms of absorption rate from the intestinal tract.
【0005】以上のような現状から、元来優れたアミノ
酸バランスを有する乳タンパク質、特に乳清タンパク質
を酵素で加水分解したオリゴペプチド混合物を製造する
方法が多数開発されている。それらのいくつかを例示す
れば次のとおりである。Under the above circumstances, many methods have been developed for producing a milk protein originally having an excellent amino acid balance, particularly an oligopeptide mixture obtained by hydrolyzing whey protein with an enzyme. Some examples of them are as follows.
【0006】特開平2−138991号公報には、ペプ
チドの分子量が1000以下、抗原性を呈さず、原料タ
ンパク質中の芳香族アミノ酸が90%以上遊離アミノ酸
になるまで酵素分解した後、ゲルろ過法によって遊離の
芳香族アミノ酸を除去して遊離アミノ酸含量を20%以
下にすることよりなる低分子ペプチドの製造方法が示さ
れている。JP-A-2-138991 discloses that the peptide has a molecular weight of 1000 or less, does not exhibit antigenicity, and is enzymatically decomposed until 90% or more of free amino acids are contained in the starting protein, and then gel filtration method is used. Discloses a method for producing a low molecular weight peptide, which comprises removing free aromatic amino acids to reduce the free amino acid content to 20% or less.
【0007】特開平4−112753号公報には、ペプ
チドの分子量が10000以下、平均鎖長が3〜8、遊
離アミノ酸含量が20%以下、抗原性がβ−ラクトグロ
ブリンの1/10000以下となるように耐熱性の酵素
で60〜80℃で加水分解することよりなる乳清タンパ
ク加水分解物の製造法が示されている。JP-A-4-112753 discloses that the peptide has a molecular weight of 10,000 or less, an average chain length of 3 to 8, a free amino acid content of 20% or less, and an antigenicity of 1/10000 or less of β-lactoglobulin. As described above, a method for producing a whey protein hydrolyzate, which comprises hydrolyzing with a thermostable enzyme at 60 to 80 ° C, is shown.
【0008】特開平4−248959号公報には、ペプ
チドの分子量が2000以下、抗原残存活性が10-4以
下、遊離アミノ酸含量が5%以下となるようにバチルス
・ズブチリス(Bacillus subtilis)
由来のエンドペプチダーゼ、トリプシンおよび/または
キモトリプシンの混合酵素で加水分解することよりなる
乳清タンパク質由来のオリゴペプチド混合物の製造法が
示されている。[0008] Japanese Patent Laid-Open No. 4-248959, the following molecular weight peptides 2000, residual antigenic activity is 10-4 or less, as free amino acid content of 5% or less Bacillus subtilis (Bacillus subtilis)
A method for producing a mixture of oligopeptides derived from whey protein, which comprises hydrolyzing with a mixed enzyme of endopeptidase, trypsin and / or chymotrypsin from which has been shown.
【0009】[0009]
【発明が解決しようとする課題】しかしながら、上記特
開平2−138991号公報の発明においては、芳香族
アミノ酸含量が極めて少なく、元来乳清タンパク質が有
している優れたアミノ酸バランスを著しく損なってお
り、また、風味については何ら言及されていない。However, in the invention of JP-A-2-138991 described above, the aromatic amino acid content is extremely low, and the excellent amino acid balance originally possessed by whey protein is significantly impaired. No mention is made of the flavor.
【0010】また、上記特開平4−112753号公報
の発明においては分子量分布が10000以下、メイン
ピークが1000〜5000と大きなペプチドを含んで
おり、さらに上記特開平4−248959号公報の発明
においてもpH4.5〜5.5で加熱すると多量の沈で
ん物が生じるほど大きな分子量のペプチドが残存してお
り、それぞれ腸管吸収の点から満足なものではない。Further, in the invention of the above-mentioned JP-A-4-112753, a peptide having a large molecular weight distribution of 10,000 or less and a main peak of 1000 to 5000 is contained, and the invention of the above-mentioned JP-A-4-248959 is also included. Peptides having a large molecular weight remain so as to produce a large amount of precipitate when heated at pH 4.5 to 5.5, which are not satisfactory in terms of intestinal absorption.
【0011】以上のように、乳清タンパク質を酵素分解
することによって得られるオリゴペプチド混合物につい
ては、腸管吸収性に優れ、アミノ酸バランスが良く、風
味が良好という全ての条件を満たし、低アレルギー性の
食品および経腸栄養剤の窒素源として利用可能なものは
従来知られていなかった。As described above, the oligopeptide mixture obtained by enzymatically degrading whey protein satisfies all the conditions of excellent intestinal absorbability, good amino acid balance, and good flavor, and is hypoallergenic. What was available as a nitrogen source for foods and enteral nutrients has not been heretofore known.
【0012】本発明は、このような技術の現状に鑑み、
上記したようなすぐれた性質を有する新規なオリゴペプ
チド混合物を新たに開発する目的でなされたものであ
る。The present invention has been made in view of the current state of the art.
It was made for the purpose of newly developing a novel oligopeptide mixture having excellent properties as described above.
【0013】[0013]
【課題を解決するための手段】本発明者らは、上記目的
を達成するために各方面から検討した結果、乳清タンパ
ク質をバチルス属由来のプロテアーゼと放線菌由来のプ
ロテアーゼの2種類の酵素により加水分解し、酵素と不
溶性の加水分解物を除去することにより、乳清タンパク
質本来のアミノ酸バランスを維持したまま腸管吸収性に
優れ、風味が良好なオリゴペプチド混合物が得られるこ
とを見いだした。Means for Solving the Problems As a result of investigations from various aspects to achieve the above object, the present inventors have found that whey protein is produced by two kinds of enzymes, a protease derived from Bacillus and a protease derived from actinomycete. By hydrolyzing and removing the enzyme and the insoluble hydrolyzate, it was found that an oligopeptide mixture having excellent intestinal absorbability and good flavor can be obtained while maintaining the original amino acid balance of whey protein.
【0014】さらに、バチルス属由来のプロテアーゼ、
放線菌由来のプロテアーゼに付け加えて、トリプシンお
よび/またはキモトリプシンを併用して加水分解しても
同様にオリゴペプチド混合物が得られることを見いだ
し、本発明を完成した。Further, a Bacillus-derived protease,
The inventors have found that an oligopeptide mixture can be similarly obtained by hydrolyzing in combination with trypsin and / or chymotrypsin in addition to the protease derived from actinomycetes, and completed the present invention.
【0015】以下、本発明を詳しく説明する。The present invention will be described in detail below.
【0016】本発明を実施するには、乳清タンパク質を
特定の酵素で処理しなければならないが、本発明におい
て使用される乳清タンパク質としては、乳清タンパク質
濃縮物(Whey Protein Concentr
ate、WPC)や乳清タンパク質分離物(Whey
Protein Isolate、WPI)があげられ
る。In order to carry out the present invention, the whey protein must be treated with a specific enzyme. The whey protein used in the present invention includes whey protein concentrate (Whey Protein Concentr).
ate, WPC) and whey protein isolate (Whey)
Protein Isolate (WPI).
【0017】WPCは、チーズやカゼインを製造する際
に生じる乳清を限外ろ過・ゲルろ過・乳清結晶分離など
の方法で処理し、タンパク質含量を通常35〜85%
(固形分換算)まで高めたものである。In WPC, whey produced during the production of cheese or casein is treated by a method such as ultrafiltration, gel filtration or whey crystal separation, and the protein content is usually 35 to 85%.
It is increased to (solid content conversion).
【0018】WPIは、WPCと区別されるものであっ
て、イオン交換法などの方法でタンパク質含量を95%
(固形分換算)以上という高純度に精製した未変性乳清
タンパク質である。WPI is distinguished from WPC and has a protein content of 95% by a method such as an ion exchange method.
It is an undenatured whey protein that has been purified to a high purity (as calculated as solid content) or higher.
【0019】また、アミノ酸バランスを大きく変化させ
ない範囲内で、イオン交換法・疎水的吸着法などの方法
により乳清タンパク質中のβ−ラクトグロブリンやα−
ラクトアルブミンの一部を除去したWPCを使用するこ
ともできる。Further, within a range that does not significantly change the amino acid balance, β-lactoglobulin or α-lactoglobulin in whey protein can be prepared by a method such as an ion exchange method or a hydrophobic adsorption method.
It is also possible to use WPC from which a part of lactalbumin has been removed.
【0020】このような乳清タンパク質を酵素によって
加水分解するのであるが、本発明において使用される酵
素は、バチルス(Bacillus)属由来のプロテア
ーゼ、放線菌由来のプロテアーゼおよび動物臓器由来の
トリプシン、キモトリプシンである。これらの酵素は、
いずれも市販品を使用することができる。Such whey protein is hydrolyzed by an enzyme. The enzyme used in the present invention is a protease derived from the genus Bacillus, a protease derived from actinomycete and trypsin and chymotrypsin derived from animal organs. Is. These enzymes are
In each case, a commercial product can be used.
【0021】例えば、バチルス属由来のプロテアーゼと
しては、ビオプラーゼ(ナガセ生化学工業社)、アルカ
ラーゼ(ノボ社)、プロテアーゼNアマノ(天野製薬
社)などがあげられるし、放線菌由来のプロテアーゼと
しては、アクチナーゼ(科研ファルマ社)、プロナーゼ
(シグマ社)などがあげられる。Examples of Bacillus-derived proteases include bioprase (Nagase Seikagaku Corp.), Alcalase (Novo), Protease N Amano (Amano Pharmaceutical Co., Ltd.), and actinomycete-derived proteases include: Examples include actinase (Kaken Pharma Co., Ltd.) and pronase (Sigma Co.).
【0022】本発明においては、上述の乳清タンパク質
をタンパク質濃度で1〜20%、好ましくは5〜10%
となるように水溶液を調製し、加熱殺菌した後または加
熱殺菌することなく酵素分解を行う。In the present invention, the above whey protein is contained in a protein concentration of 1 to 20%, preferably 5 to 10%.
An aqueous solution is prepared so that the above condition is obtained, and enzymatic decomposition is performed after heat sterilization or without heat sterilization.
【0023】酵素分解は、水酸化ナトリウムや水酸化カ
リウムなどのアルカリ液や塩酸やクエン酸などの酸液を
用いて、酵素の至適pHであるpH7〜8に調整しなが
ら40〜60℃に保持し、3〜48時間、好ましくは6
〜24時間行う。The enzymatic decomposition is carried out at 40 to 60 ° C. using an alkaline solution such as sodium hydroxide or potassium hydroxide or an acid solution such as hydrochloric acid or citric acid while adjusting the pH to 7-8 which is the optimum pH of the enzyme. Hold for 3 to 48 hours, preferably 6
~ 24 hours.
【0024】使用する酵素は、一度にまとめて添加して
もよいし、別々に添加してもよい。またこのとき、添加
する順序は問わない。The enzymes to be used may be added all at once or separately. At this time, the order of addition is not limited.
【0025】酵素分解後、加熱により酵素を失活し、遠
心分離・精密ろ過・限外ろ過などの方法により酵素と不
溶性の加水分解物を除去する。あるいは酵素分解後加熱
失活せず、分画分子量20000以下の限外ろ過膜を使
用して限外ろ過を行うなどの方法により、酵素と不溶性
の加水分解物を除去してもよい。After the enzymatic decomposition, the enzyme is inactivated by heating, and the enzyme and insoluble hydrolyzate are removed by a method such as centrifugation, microfiltration or ultrafiltration. Alternatively, the enzyme and the insoluble hydrolyzate may be removed by a method such as performing ultrafiltration using an ultrafiltration membrane having a molecular weight cutoff of 20000 or less without deactivating by heating after enzymatic decomposition.
【0026】このようにして得られたオリゴペプチド混
合物は、通常、灰分が5〜20%(固形分換算)含まれ
ているが、必要があれば電気透析などの方法で脱塩処理
することも可能である。The oligopeptide mixture thus obtained usually contains 5 to 20% (as solid content) of ash, but if necessary, it may be desalted by a method such as electrodialysis. It is possible.
【0027】また、このようにして得られたオリゴペプ
チド混合物は、公知の方法で凍結・濃縮・乾燥すること
もできる。The oligopeptide mixture thus obtained can also be frozen, concentrated and dried by a known method.
【0028】以上のようにして目的とするオリゴペプチ
ド混合物が得られるが、例えば、後述する試験方法によ
り測定すると、平均鎖長3〜5、最大分子量1500以
下、抗原性がβ−ラクトグロブリンの1/10000以
下、そして苦味や旨味が極めて少ないものである。The desired oligopeptide mixture is obtained as described above. For example, when measured by the test method described below, the average chain length is 3 to 5, the maximum molecular weight is 1500 or less, and the antigenicity is 1 of β-lactoglobulin. / 10,000 or less, and very little bitterness and umami.
【0029】以下、試験例及び実施例について述べる
が、そこで用いられる数値は、次のような試験方法によ
って求めたものである。The test examples and examples will be described below. The numerical values used therein are obtained by the following test method.
【0030】試験方法:Test method:
【0031】(平均鎖長)オリゴペプチド混合物中のペ
プチドの平均鎖長は、次式により求めた。 (OTA−FA)/(OFA−FA) 但し式中、 OTA:オリゴペプチド混合物中の全アミノ基 OFA:オリゴペプチド混合物中の遊離アミノ基 FA:遊離アミノ酸相当のアミノ基(Average Chain Length) The average chain length of the peptides in the oligopeptide mixture was determined by the following formula. (OTA-FA) / (OFA-FA) where OTA: all amino groups in the oligopeptide mixture OFA: free amino group in the oligopeptide mixture FA: amino group corresponding to free amino acid
【0032】オリゴペプチド混合物の全アミノ基(OT
A)は、試料を強酸性または強塩基性下で加水分解後、
アミノ酸自動分析機で分析したアミノ酸組成より計算し
た。All amino groups of the oligopeptide mixture (OT
A) is, after hydrolysis of the sample under strong acidity or basicity,
It was calculated from the amino acid composition analyzed by an amino acid automatic analyzer.
【0033】なお、このとき、トリプトファンは8N水
酸化ナトリウムで110℃22時間加水分解した試料に
より、システインおよびメチオニンは過ギ酸処理後6N
塩酸で110℃22時間加水分解した試料により、その
他のアミノ酸は6N塩酸で110℃22時間加水分解し
た試料により測定した値を用いた。At this time, tryptophan was hydrolyzed with 8N sodium hydroxide at 110 ° C. for 22 hours, and cysteine and methionine were treated with 6N after treatment with formic acid.
The values measured by the sample hydrolyzed with hydrochloric acid at 110 ° C. for 22 hours and the values of other amino acids measured by the sample hydrolyzed with 6N hydrochloric acid at 110 ° C. for 22 hours were used.
【0034】オリゴペプチド混合物の遊離アミノ基(O
FA)は、TNBS(トリニトロベンゼンスルホン酸)
法により測定した。The free amino groups (O
FA) is TNBS (trinitrobenzene sulfonic acid)
It was measured by the method.
【0035】遊離アミノ酸相当のアミノ基(FA)は、
試料を0.1N塩酸で希釈した後、アミノ酸自動分析機
で分析した遊離アミノ酸組成より計算した。The amino group (FA) corresponding to the free amino acid is
The sample was diluted with 0.1 N hydrochloric acid and then calculated from the free amino acid composition analyzed by an amino acid automatic analyzer.
【0036】(最大分子量)オリゴペプチド混合物中の
最大ペプチドの分子量は、アサヒパックGS−320
(直径7.6mm、長さ500mm)を用いた高速液体
クロマトグラフィーにより測定した。クロマトグラム上
の最初のピーク(ただし、ショルダーのある場合は最初
のショルダー)の溶出時間と、別に作成した較正曲線か
ら最大分子量を求めた。(Maximum Molecular Weight) The molecular weight of the maximum peptide in the oligopeptide mixture was determined by Asahi Pack GS-320.
(Diameter 7.6 mm, length 500 mm) was measured by high performance liquid chromatography. The maximum molecular weight was determined from the elution time of the first peak on the chromatogram (however, if there is a shoulder, the first shoulder) and the calibration curve prepared separately.
【0037】(抗原性)オリゴペプチド混合物の抗原性
は、ELISA抑制試験法により、ウサギ抗β−ラクト
グロブリン血清とアルカリフォスファターゼ標識ヤギ抗
ウサギIgG抗体を用いて測定した。β−ラクトグロブ
リンとオリゴペプチド混合物について、それぞれ全く抑
制のかからない最大濃度を比較し、その比率を示した。(Antigenicity) The antigenicity of the oligopeptide mixture was measured by an ELISA inhibition test method using rabbit anti-β-lactoglobulin serum and alkaline phosphatase-labeled goat anti-rabbit IgG antibody. For β-lactoglobulin and the oligopeptide mixture, the maximum concentrations at which there was no inhibition were compared, and the ratios are shown.
【0038】(苦味および旨味)オリゴペプチド混合物
の苦味および旨味は、タンパク質濃度を2%に調整した
液について、20〜30代の16名の熟練したパネルに
より官能的に評価した。評価結果を次のように示した。(Bitterness and umami) The bitterness and umami of the oligopeptide mixture were sensorially evaluated by a skilled panel of 16 people in their 20s to 30s with respect to the liquid in which the protein concentration was adjusted to 2%. The evaluation results are shown below.
【0039】苦味 −:苦味があるとした人数が 0〜4 名/16名 ±: 同 5〜11名/16名 +: 同 12〜16名/16名Bitterness: 0 to 4 people / 16 people with bitterness ±: 5 to 11 people / 16 people +: 12 to 16 people / 16 people
【0040】旨味 −:旨味があるとした人数が 0〜4 名/16名 ±: 同 5〜11名/16名 +: 同 12〜16名/16名Umami −: The number of people who have umami is 0 to 4 people / 16 people ±: The same number 5 to 11 people / 16: The same number 12 to 16 people / 16 people
【0041】[0041]
【試験例】WPI(タンパク質含量92%)55gを水
900gに溶解し、80℃で10分間加熱殺菌した。5
0℃に冷却後、酵素を一度に添加し、pH7に調整しな
がら50℃で24時間保持して加水分解した。次いで9
0℃で10分間加熱して酵素を失活させた後、遠心分離
して酵素と不溶性の加水分解物を除去した。各種酵素を
使用して調製した試料について平均鎖長、最大分子量、
抗原性、苦味および旨味を評価した。試験結果を表1、
表2で示される第1表に示した。[Test Example] 55 g of WPI (protein content 92%) was dissolved in 900 g of water, and heat sterilized at 80 ° C. for 10 minutes. 5
After cooling to 0 ° C, the enzyme was added all at once, and the mixture was kept at 50 ° C for 24 hours while being adjusted to pH 7 for hydrolysis. Then 9
After heating at 0 ° C. for 10 minutes to inactivate the enzyme, centrifugation was performed to remove the enzyme and insoluble hydrolyzate. Average chain length, maximum molecular weight of samples prepared using various enzymes,
Antigenicity, bitterness and umami were evaluated. The test results are shown in Table 1,
The results are shown in Table 1 shown in Table 2.
【0042】[0042]
【表1】 [Table 1]
【0043】[0043]
【表2】 [Table 2]
【0044】上記結果から明らかなように、いずれの試
験区でも抗原性はβ−ラクトグロブリンの1/1000
0以下であり、ペプチドの平均鎖長は3〜5の範囲内で
あった。As is clear from the above results, the antigenicity is 1/1000 that of β-lactoglobulin in any of the test groups.
It was 0 or less, and the average chain length of the peptide was within the range of 3 to 5.
【0045】しかし、エクソペプチダーゼを用いない試
験区1〜3では最大分子量が1800以上であり、また
苦味を感じる人がやや多かった。However, in test groups 1 to 3 in which no exopeptidase was used, the maximum molecular weight was 1800 or more, and there were a few people who felt bitterness.
【0046】また、エクソペプチダーゼとしてアスペル
ギルス(Aspergillus)属由来の酵素(例え
ば、プロテアーゼAアマノ、デナチームAP)を用いた
試験区4〜6では、最大分子量は1500以下であり、
苦味を感じる人はほとんどいなかったが、遊離アミノ酸
が多く、旨味を感じる人が多かった。In test groups 4 to 6 using an enzyme derived from the genus Aspergillus as an exopeptidase (for example, Protease A Amano, Denazyme AP), the maximum molecular weight is 1500 or less,
Few people had a bitter taste, but many had a lot of free amino acids and had a good taste.
【0047】一方、本発明で記載した酵素の組み合せで
ある試験区7〜9では、最大分子量は1500以下であ
り、苦味や旨味を感じる人はほとんどいなかった。On the other hand, in the test groups 7 to 9 which are combinations of the enzymes described in the present invention, the maximum molecular weight was 1500 or less, and few people felt bitterness or umami.
【0048】以上のように、平均鎖長3〜5、最大分子
量1500以下、抗原性がβ−ラクトグロブリンの1/
10000以下、そして苦味や旨味が極めて少ないとい
う全ての条件を満たすオリゴペプチド混合物を調製する
ためには、バチルス属由来のプロテアーゼと放線菌由来
のプロテアーゼの2種類の酵素、またはバチルス属由来
のプロテアーゼ、放線菌由来のプロテアーゼ、トリプシ
ンおよび/またはキモトリプシンからなる3または4種
類の酵素によって加水分解することが必要であった。As described above, the average chain length is 3 to 5, the maximum molecular weight is 1500 or less, and the antigenicity is 1 / l of β-lactoglobulin.
In order to prepare an oligopeptide mixture that satisfies all the conditions of 10,000 or less and extremely little bitterness and umami, two kinds of enzymes, a protease derived from Bacillus and a protease derived from actinomycete, or a protease derived from Bacillus, It was necessary to hydrolyze with 3 or 4 enzymes consisting of actinomycete-derived proteases, trypsin and / or chymotrypsin.
【0049】[0049]
【実施例1】WPC(タンパク質含量78%)770g
を水9200gに溶解し、75℃で10分間殺菌後40
℃に冷却した。アルカラーゼ(ノボ社)2500単位/
gタンパク質およびアクチナーゼ(科研ファルマ社)5
000単位/gタンパク質を添加し、10%水酸化ナト
リウム溶液でpHを7に調整しながら40℃で12時間
加水分解した。90℃で10分間加熱して酵素を失活さ
せた後、遠心分離して上清を回収し、これを乾燥してオ
リゴペプチド混合物粉末720gを得た。Example 1 WPC (protein content 78%) 770 g
Is dissolved in 9200 g of water and sterilized at 75 ° C for 10 minutes, then 40
Cooled to ° C. Alcalase (Novo) 2500 units /
g protein and actinase (Kaken Pharma Co., Ltd.) 5
000 units / g protein was added, and hydrolysis was carried out at 40 ° C. for 12 hours while adjusting the pH to 7 with a 10% sodium hydroxide solution. After heating at 90 ° C. for 10 minutes to inactivate the enzyme, centrifugation was performed to collect a supernatant, which was dried to obtain 720 g of an oligopeptide mixture powder.
【0050】この粉末のペプチドの平均鎖長は4.2、
最大分子量は1200、抗原性はβ−ラクトグロブリン
の1/10000以下であり、苦味や旨味はほとんどな
いものであった。The average peptide chain length of the peptide was 4.2,
The maximum molecular weight was 1200 and the antigenicity was 1/10000 or less that of β-lactoglobulin, and there was almost no bitterness or umami.
【0051】[0051]
【実施例2】WPI(タンパク質含量92%)1000
gを水8800gに溶解した。これにビオプラーゼ(ナ
ガセ生化学工業社)2200単位/gタンパク質、トリ
プシン(ノボ社)1300単位/gタンパク質、キモト
リプシン(ノボ社)90単位/gタンパク質およびアク
チナーゼ(科研ファルマ社)1100単位/gタンパク
質を添加し、10%水酸化ナトリウム溶液でpHを7.
5に調整しながら50℃で20時間加水分解した。これ
を分画分子量20000の限外ろ過膜で限外ろ過して酵
素と不溶性の加水分解物を除去した。さらに、電気透析
装置を用いて電気伝導度が1/10となるまで脱塩した
後乾燥して、オリゴペプチド混合物粉末940gを得
た。Example 2 WPI (protein content 92%) 1000
g was dissolved in 8800 g of water. Biopulase (Nagase Seikagaku Corp.) 2200 units / g protein, trypsin (Novo Corp.) 1300 units / g protein, chymotrypsin (Novo Corp.) 90 units / g protein and actinase (Kaken Pharma Corp.) 1100 units / g protein Add and adjust pH to 7 with 10% sodium hydroxide solution.
While adjusting to 5, hydrolysis was carried out at 50 ° C. for 20 hours. This was subjected to ultrafiltration with an ultrafiltration membrane having a molecular weight cut off of 20,000 to remove the enzyme and the insoluble hydrolyzate. Further, it was desalted using an electrodialyzer until the electric conductivity became 1/10 and then dried to obtain 940 g of an oligopeptide mixture powder.
【0052】この粉末の2%溶液は、pH4〜5で加熱
しても全く沈でん物が認められず、苦味や旨味はほとん
どないものであった。また、ペプチドの平均鎖長は3.
8、最大分子量は1000、抗原性はβ−ラクトグロブ
リンの1/10000以下であった。A 2% solution of this powder showed no sediment at all even when heated at pH 4 to 5, and had little bitterness or umami. The average chain length of the peptides is 3.
8, the maximum molecular weight was 1000, and the antigenicity was 1/10000 or less of β-lactoglobulin.
【0053】[0053]
【実施例3】pH4.6のチーズホエーを陽イオン交換
樹脂Indion S3(ライフテクノロジー社)に通
液し、α−ラクトアルブミンの一部を除くほとんどの乳
清タンパク質を吸着させた。これを水酸化ナトリウム溶
液を使用してpH9で溶出し、分画分子量20000の
限外ろ過膜で濃縮後噴霧乾燥してタンパク質含量88%
のWPCを得た。このWPCのタンパク質中β−ラクト
グロブリンは80%、α−ラクトアルブミンは6%であ
った。Example 3 Cheese whey having a pH of 4.6 was passed through a cation exchange resin Indion S3 (Life Technology Co., Ltd.) to adsorb most whey proteins except a part of α-lactalbumin. This was eluted with sodium hydroxide solution at pH 9, concentrated with an ultrafiltration membrane having a molecular weight cut off of 20,000, and then spray-dried to give a protein content of 88%.
Got the WPC. Β-lactoglobulin in the protein of this WPC was 80%, and α-lactalbumin was 6%.
【0054】このWPC570gを水9400gに溶解
し、ビオプラーゼ(ナガセ生化学工業社)2000単位
/gタンパク質、トリプシン(ノボ社)2500単位/
gタンパク質を添加し、10%水酸化ナトリウム溶液で
pHを8に調整しながら50℃で8時間加水分解した。
次に、アクチナーゼ(科研ファルマ社)1250単位/
gタンパク質を添加し、pHを7に調整しながら50℃
で16時間加水分解した。120℃で15秒間加熱して
酵素を失活させた後、遠心分離して上清を回収し、さら
に孔径0.45μの精密ろ過膜でろ過したものを乾燥し
てオリゴペプチド混合物粉末530gを得た。570 g of this WPC was dissolved in 9400 g of water, and biopulase (Nagase Seikagaku Co., Ltd.) 2000 units / g protein, trypsin (Novo Corp.) 2500 units /
g-protein was added and hydrolysis was carried out at 50 ° C. for 8 hours while adjusting the pH to 8 with a 10% sodium hydroxide solution.
Next, actinase (Kaken Pharma Co.) 1250 units /
Add g protein and adjust pH to 7 at 50 ℃
For 16 hours. After heating at 120 ° C. for 15 seconds to inactivate the enzyme, centrifugation was performed to collect the supernatant, which was further filtered through a microfiltration membrane having a pore size of 0.45μ and dried to obtain 530 g of an oligopeptide mixture powder. It was
【0055】この粉末の2%溶液は、pH4〜5で加熱
しても全く沈でん物が認められず、苦味や旨味はほとん
どないものであった。また、ペプチドの平均鎖長は3.
6、最大分子量は1000、抗原性はβ−ラクトグロブ
リンの1/10000以下であった。A 2% solution of this powder showed no precipitate even when heated at pH 4 to 5, and had almost no bitterness or umami. The average chain length of the peptides is 3.
6, the maximum molecular weight was 1000, and the antigenicity was 1/10000 or less of β-lactoglobulin.
【0056】[0056]
【発明の効果】本発明の製造方法により、乳清タンパク
質から腸管吸収性に優れ、アミノ酸バランスが良く、抗
原性が無く、風味の良好なオリゴペプチド混合物を収率
良く得ることができる。Industrial Applicability According to the production method of the present invention, an oligopeptide mixture having excellent intestinal absorbability, good amino acid balance, no antigenicity, and good flavor can be obtained from whey protein in good yield.
【0057】また、本発明に係るオリゴペプチド混合物
は、次のような用途に使用することが可能である。The oligopeptide mixture according to the present invention can be used for the following purposes.
【0058】(1)消化吸収能の低い乳幼児、高令者お
よび手術前後の病人への栄養補給剤、経腸栄養剤。 (2)乳幼児から小児に多いアレルギー性疾患者への栄
養補給剤、低アレルギー性食品。 (3)妊娠期特にその後期において、胎児へのアレルギ
ー体質の移行を抑制するため食事制限を行っている妊婦
への栄養補給剤。(1) A nutritional supplement and enteral nutritional supplement for infants, elderly people and sick people before and after surgery having low digestive and absorption ability. (2) A nutritional supplement and a hypoallergenic food for infants and children with allergic diseases. (3) A nutritional supplement for pregnant women who are diet-restricted in order to suppress the transfer of allergic constitution to the fetus during the pregnancy period, especially in the latter period.
フロントページの続き (72)発明者 金子 哲夫 東京都東村山市栄町1−21−3 明治乳業 株式会社中央研究所内 (72)発明者 丸山 哲彦 東京都東村山市栄町1−21−3 明治乳業 株式会社中央研究所内Front Page Continuation (72) Inventor Tetsuo Kaneko 1-21-3 Sakaemachi, Higashimurayama, Tokyo Meiji Dairy Co., Ltd. Central Research Institute (72) Tetsuhiko Maruyama 1-21-3 Sakaemachi, Higashimurayama, Tokyo Meiji Dairy Co., Ltd. In the laboratory
Claims (4)
テアーゼと放線菌由来のプロテアーゼの2種類の酵素に
よって加水分解した後、酵素と不溶性の加水分解物を除
去することを特徴とするオリゴペプチド混合物の製造方
法。1. A mixture of oligopeptides characterized in that after whey protein is hydrolyzed by two kinds of enzymes, a protease derived from Bacillus and a protease derived from actinomycete, the enzyme and insoluble hydrolyzate are removed. Production method.
ンを使用して加水分解することを特徴とする請求項1に
記載の製造方法。2. The production method according to claim 1, further comprising hydrolyzing with trypsin and / or chymotrypsin.
って製造してなるオリゴペプチド混合物。3. An oligopeptide mixture produced by the method according to claim 1 or 2.
5、最大分子量1500以下、抗原性がβ−ラクトグロ
ブリンの1/10000以下、そして苦味や旨味が極め
て少ないものであることを特徴とする請求項3に記載の
オリゴペプチド混合物。4. A mixture of oligopeptides having an average chain length of 3 to
5. The oligopeptide mixture according to claim 3, wherein the maximum molecular weight is 1500 or less, the antigenicity is 1/10000 or less of β-lactoglobulin, and the bitterness and umami taste are extremely small.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16501493A JP3222638B2 (en) | 1993-06-11 | 1993-06-11 | Oligopeptide mixture and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16501493A JP3222638B2 (en) | 1993-06-11 | 1993-06-11 | Oligopeptide mixture and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06343422A true JPH06343422A (en) | 1994-12-20 |
JP3222638B2 JP3222638B2 (en) | 2001-10-29 |
Family
ID=15804204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16501493A Expired - Lifetime JP3222638B2 (en) | 1993-06-11 | 1993-06-11 | Oligopeptide mixture and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3222638B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221423B1 (en) | 1998-04-13 | 2001-04-24 | Protein Technologies Int'l Inc. | Short-chained peptide material |
JP2007091653A (en) * | 2005-09-29 | 2007-04-12 | Rheology Kino Shokuhin Kenkyusho:Kk | Medicinal composition, and medicine and health food containing the composition |
JP2008022826A (en) * | 2006-07-25 | 2008-02-07 | Fuji Oil Co Ltd | Method for producing soybean protein hydrolysate |
WO2010112546A1 (en) * | 2009-04-02 | 2010-10-07 | Novozymes A/S | Process for making a milk-based protein hydrolysate |
JP2011502480A (en) * | 2007-11-07 | 2011-01-27 | ミード ジョンソン ニュートリション カンパニー | A method for reducing the bitterness and improving the flavor of hydrolyzed infant formula without protein |
EP2436389A1 (en) * | 2010-10-01 | 2012-04-04 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
-
1993
- 1993-06-11 JP JP16501493A patent/JP3222638B2/en not_active Expired - Lifetime
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221423B1 (en) | 1998-04-13 | 2001-04-24 | Protein Technologies Int'l Inc. | Short-chained peptide material |
JP2007091653A (en) * | 2005-09-29 | 2007-04-12 | Rheology Kino Shokuhin Kenkyusho:Kk | Medicinal composition, and medicine and health food containing the composition |
JP2008022826A (en) * | 2006-07-25 | 2008-02-07 | Fuji Oil Co Ltd | Method for producing soybean protein hydrolysate |
JP2011502480A (en) * | 2007-11-07 | 2011-01-27 | ミード ジョンソン ニュートリション カンパニー | A method for reducing the bitterness and improving the flavor of hydrolyzed infant formula without protein |
CN105661553A (en) * | 2009-04-02 | 2016-06-15 | 诺维信公司 | Process for making a milk-based protein hydrolysate |
CN102378581A (en) * | 2009-04-02 | 2012-03-14 | 诺维信公司 | Process for making a milk-based protein hydrolysate |
US9259023B2 (en) | 2009-04-02 | 2016-02-16 | Novozymes A/S | Process for making a milk-based protein hydrolysate |
WO2010112546A1 (en) * | 2009-04-02 | 2010-10-07 | Novozymes A/S | Process for making a milk-based protein hydrolysate |
EP2436389A1 (en) * | 2010-10-01 | 2012-04-04 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
WO2012042013A1 (en) * | 2010-10-01 | 2012-04-05 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
AU2011310101B2 (en) * | 2010-10-01 | 2016-09-08 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
EP3081225A1 (en) * | 2010-10-01 | 2016-10-19 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
US9486004B2 (en) | 2010-10-01 | 2016-11-08 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
AU2016247052B2 (en) * | 2010-10-01 | 2017-12-14 | Société des Produits Nestlé S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
EP3639838A1 (en) * | 2010-10-01 | 2020-04-22 | Société des Produits Nestlé S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
Also Published As
Publication number | Publication date |
---|---|
JP3222638B2 (en) | 2001-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU591230B2 (en) | A process for the preparation of a heat resistant non-bitter water-soluble peptide product, the product produced by the process, and nutrients, refreshments and dietetics comprising the product | |
US6395508B1 (en) | Peptide mixture and products thereof | |
JPH05505304A (en) | Method for producing enzymatic hydrolyzate | |
CLEGG et al. | Dietary enzymic hydrolysates of protein with reduced bitterness | |
JPH02182155A (en) | Partial hydrolysate of whey protein, enzymatic process for producing it, and special edible dairy produce for hypallergic nourishment containing it | |
US6451552B1 (en) | Method for the selective degradation of milk protein in the presence of other milk proteins | |
NZ258207A (en) | Whey protein with low phosphorus content | |
JPH10507641A (en) | Process for producing milk protein hydrolysates, the milk protein hydrolysates and use of the milk protein hydrolysates | |
US6908633B2 (en) | Protein hydrolyzates, process for producing the same and drinks and foods containing the protein hydrolyzates | |
JP3222638B2 (en) | Oligopeptide mixture and method for producing the same | |
JP2959747B2 (en) | Savory whey protein hydrolyzate and method for producing the same | |
JP4444450B2 (en) | Method for producing protein hydrolyzate | |
JPH07203844A (en) | Production of whey protein hydrolyzate excellent in emulsifiability and thermal stability and antiallergic modified milk using the same whey protein hydrolyzate | |
JPH055000A (en) | Low-aloergenic emzymolyzed peptide composition with orally tolerant inductivity | |
JPH04248959A (en) | Oligopeptide mixture and its production | |
JP3682994B2 (en) | Process for producing peptide mixtures with low phenylalanine content | |
JPH05209000A (en) | Peptide composition having decreased allergenicity | |
JPH10271958A (en) | Production of protein hydrolysate reduced in smell | |
JPH05344847A (en) | Low antigenic decomposed protein free from disagreeable taste and its production | |
JP2887302B2 (en) | Casein phospho-oligopeptide mixture, method for producing the same, and health food containing the mixture | |
JPH04365444A (en) | Antiallergic formulated milk | |
AU701507B2 (en) | Peptide mixture and products thereof | |
JPH0622446B2 (en) | Method for producing easily soluble milk protein hydrolyzate having no unpleasant taste | |
NZ203350A (en) | Preparing protein for enzymatic hydrolysis | |
JPH05137515A (en) | Low-antigenic decomposed protein free from disagreeable taste and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 12 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 12 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 12 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 12 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
EXPY | Cancellation because of completion of term |